Intrahepatic Cholangiocarcinoma: Clinical Aspects, Pathology and Treatment
Author Information
Author(s): Richard T. Schlinkert, David M. Nagorney, Jon A. Van Heerden, Martin A. Adson
Primary Institution: Mayo Clinic
Hypothesis
To further define the clinicopathology and surgical management of intrahepatic cholangiocarcinoma.
Conclusion
Surgical resection remains the only therapeutic modality that may afford prolonged survival for patients with intrahepatic cholangiocarcinoma.
Supporting Evidence
- Jaundice occurred in only 27% of patients with intrahepatic cholangiocarcinoma.
- 81% of patients had unresectable tumors due to advanced disease stage.
- Six patients had curative resections with two surviving disease-free for over 5 years.
- Chronic exposure to tobacco was present in 51% of patients.
- Median survival for patients with curative resection was 2.8 years.
Takeaway
Intrahepatic cholangiocarcinoma is a rare liver cancer that often goes undiagnosed until it's too late, but surgery can help some patients live longer.
Methodology
A review of clinical presentations, demographics, and surgical management of 32 patients with intrahepatic cholangiocarcinoma treated at the Mayo Clinic.
Limitations
The study population was small and the diagnosis is often delayed until the disease has reached an advanced stage.
Participant Demographics
17 women and 15 men with a mean age of 55 years, ranging from 31 to 81 years.
Want to read the original?
Access the complete publication on the publisher's website